STOCK TITAN

Precigen Inc - PGEN STOCK NEWS

Welcome to our dedicated page for Precigen news (Ticker: PGEN), a resource for investors and traders seeking the latest updates and insights on Precigen stock.

Overview of Precigen Inc (PGEN)

Precigen Inc is a clinical stage biopharmaceutical company that develops and refines innovative gene and cell therapies using cutting-edge synthetic biology and precision technology. With proprietary platforms such as UltraCAR-T and AdenoVerse, the company designs, builds, and regulates complex gene expression programs to address intractable diseases. Its expertise in non-viral gene transfer methods and advanced DNA construction techniques positions the company as a significant innovator across multiple therapeutic areas including immuno-oncology, autoimmune disorders, and infectious diseases.

Core Business and Technological Platforms

Precigen leverages a comprehensive suite of technologies to discover and develop next generation therapeutics. The company utilizes an advanced UltraVector platform for DNA construction, facilitating the design and assembly of gene components. Its UltraCAR-T platform, which employs a non-viral Sleeping Beauty system, enables the rapid manufacturing of personalized cell therapies with an improved safety profile and simplified logistics. Additionally, the AdenoVerse platform uses a library of engineered adenovector serotypes that efficiently deliver gene therapies aimed at modulating immune responses.

Business Model and Collaborations

The business model of Precigen is centered on leveraging its proprietary technology platforms through strategic collaborations with industry experts who bring extensive development, manufacturing, and commercial capabilities. These partnerships generate revenue primarily via technology access fees, milestone payments, royalties, and reimbursement of collaborative costs. This model provides a stable framework for continuous innovation and the effective translation of preclinical discoveries into viable clinical therapies.

Market Position and Competitive Landscape

In the competitive biotechnology arena, Precigen distinguishes itself through its robust research capabilities and a diversified portfolio of therapeutic candidates. Its unique non-viral gene transfer methods and rapid manufacturing techniques set it apart from traditional gene and cell therapy developers. By focusing resources on technologies with high clinical and commercial potential, the company addresses critical unmet needs in the therapeutic landscape, thereby reinforcing its market significance.

Operational Focus and Expertise

Precigen’s operations are built on years of scientific expertise in genetic engineering and computational model integration for therapeutic design. The company’s detailed approach to tailoring gene expression programs allows for improved functional characteristics of immune cells and precise control over therapeutic outcomes. Its methodical approach and dedication to iterative clinical development underscore its commitment to advancing medicine with precision.

Summary of Value Proposition

Precigen excels in translating complex genetic information into transformative therapies with the potential to modify the disease course in challenging therapeutic areas. By continually streamlining its research and operational models, the company ensures that its innovative techniques remain at the forefront of scientific excellence and commercial relevance. The integrated approach of technology, clinical expertise, and strategic partnerships makes Precigen a notable entity within the biopharmaceutical industry.

Rhea-AI Summary

On November 16, 2020, Precigen (Nasdaq: PGEN) announced the successful dosing of the first patients with UltraCAR-T cells made using its proprietary UltraPorator system, which aims to revolutionize the manufacturing of personalized cancer therapies. The patients participated in two Phase 1 clinical trials: PRGN-3005 for advanced ovarian cancer and PRGN-3006 for relapsed acute myeloid leukemia. This innovation streamlines manufacturing, allowing for rapid cell production within medical facilities and timely patient treatment.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
8.29%
Tags
-
Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN) reported third quarter 2020 revenues of $23.6 million, up 29% from $18.3 million in Q3 2019. The net loss narrowed to $29.5 million or $(0.18) per share, improving from $49.1 million or $(0.32) per share a year prior. Year-to-date revenues reached $83.8 million, a 14% increase from $73.7 million in 2019. Key achievements included FDA clearance for the UltraPorator system, dosing the first patient in the PRGN-2009 trial, and advancing UltraCAR-T therapies for ovarian cancer and AML.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
10.59%
Tags
-
Rhea-AI Summary

Precigen, a biopharmaceutical company, will release its third quarter 2020 financial results on November 9, 2020. The company focuses on developing gene and cell therapies for various diseases, including cancer and autoimmune disorders. In early December, Precigen plans to host a call to update stakeholders on its clinical pipeline. The firm emphasizes its commitment to precision medicine and aims to innovate in affordable biotherapeutics. Investors should stay tuned for financial performance insights and clinical progress in the upcoming announcements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
12.23%
Tags
Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN) has appointed Gaurav Vij as the new head of business development. Mr. Vij, with over 18 years of experience, will focus on accelerating strategic partnerships and enhancing the company’s pipeline programs. His prior experience includes significant roles at Gilead Sciences, Amgen, and Shire Pharmaceuticals, with a strong emphasis on oncology. This appointment aligns with Precigen's strategy to maximize value through partnerships and foster innovation in gene and cell therapies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
partnership
-
Rhea-AI Summary

Precigen (Nasdaq: PGEN) has received FDA clearance for its UltraPorator system, designed for rapid manufacturing of UltraCAR-T therapies. This system enables efficient clinical trial manufacturing for PRGN-3005 and PRGN-3006, targeting ovarian cancer and acute myeloid leukemia, respectively. The technology transfer is now complete, allowing personalized therapy delivery to patients. The UltraPorator significantly reduces processing time and contamination risks compared to traditional methods, enhancing the scalability of CAR-T therapy production. This advancement aims to transform patient access to critical cancer treatments.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.07%
Tags
-
Rhea-AI Summary

On October 9, 2020, Precigen (Nasdaq: PGEN) announced that Merck KGaA, Darmstadt, Germany, increased its ownership from 11.6% to 14.8% by converting a $25 million convertible note. This move positions Merck as Precigen's second-largest shareholder. The agreement includes the reassignment of CAR-T development rights, allowing Precigen to regain autonomy over its proprietary CAR-T technology in exchange for $150 million in stock and the convertible note. Two UltraCAR-T therapies are currently in Phase 1 trials against ovarian cancer and AML.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
29.02%
Tags
none
Rhea-AI Summary

On September 8, 2020, Precigen (Nasdaq: PGEN) announced that Helen Sabzevari, PhD, President and CEO, will present at the H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020, at 10:30 AM ET. The event will be accessible via a live webcast through Precigen’s website. Precigen focuses on innovative gene and cell therapies to address serious diseases in immuno-oncology, autoimmune disorders, and infectious diseases, advancing its clinical pipeline toward commercialization.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.92%
Tags
conferences
-
Rhea-AI Summary

Precigen, Inc. (Nasdaq: PGEN) announced the first patient has been dosed with PRGN-2009, an investigational OTS immunotherapy targeting HPV-associated solid tumors. The Phase I trial will evaluate the safety of PRGN-2009 as a monotherapy and in combination with bintrafusp alfa for recurrent or metastatic cancers. The study, facilitated through a CRADA with the National Cancer Institute, marks a significant step in developing new treatment options for patients. HPV-related cancers account for approximately 44,000 cases annually in the U.S., emphasizing the importance of this research.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
13.26%
Tags
none
-
Rhea-AI Summary

Precigen, Inc. (PGEN) released its second quarter and first half financial results for 2020, reporting total revenues of $30.4 million for Q2 and $60.3 million for the first half. The net loss was $43.4 million in Q2 ($0.26 per share) and $73.3 million in the first half ($0.45 per share), affected by non-cash charges. Key developments included advancements in the UltraPorator device and ongoing clinical trials for therapies like UltraCAR-T and AG019, demonstrating promising safety and efficacy results.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-10.16%
Tags
Rhea-AI Summary

Precigen ActoBio, a clinical-stage biotechnology firm, announced the successful completion of the primary endpoint in its Phase 1b study of AG019, focusing on safety and tolerability for early-onset type 1 diabetes. The study showed that AG019, an oral capsule, was well tolerated with no serious adverse events reported. Notably, 67% of patients exhibited a slower decline in C-peptide levels, indicating potential disease modification. The ongoing Phase 2a study will further evaluate AG019 in combination with teplizumab. This promising data supports continued development of AG019 in targeting type 1 diabetes.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.92%
Tags

FAQ

What is the current stock price of Precigen (PGEN)?

The current stock price of Precigen (PGEN) is $1.435 as of April 1, 2025.

What is the market cap of Precigen (PGEN)?

The market cap of Precigen (PGEN) is approximately 423.4M.

What is the primary focus of Precigen Inc?

Precigen Inc specializes in the discovery and development of innovative gene and cell therapies using precision synthetic biology techniques.

How does Precigen generate revenue?

The company generates revenue through strategic collaborations that involve technology access fees, milestone payments, royalties, and reimbursement of development costs.

What distinguishes Precigen's technological platforms?

Precigen is recognized for its proprietary platforms, including UltraCAR-T and AdenoVerse, which employ non-viral gene transfer and advanced DNA construction methods to create effective therapeutic solutions.

Which therapeutic areas does Precigen target?

The company focuses on addressing critical diseases in immuno-oncology, autoimmune disorders, and infectious diseases, among other high-need medical conditions.

How is Precigen positioned in the competitive biotechnology landscape?

Precigen differentiates itself with its advanced non-viral gene transfer technology and rapid manufacturing processes, enabling the development of highly specialized therapies that tackle unmet medical needs.

What role do partnerships play in Precigen's business model?

Partnerships are central to Precigen's business model, providing access to additional resources and expertise in areas such as clinical development, manufacturing, and commercialization to accelerate the translation of its therapies.
Precigen Inc

Nasdaq:PGEN

PGEN Rankings

PGEN Stock Data

423.42M
263.43M
10.01%
66.34%
7.37%
Biotechnology
Pharmaceutical Preparations
Link
United States
GERMANTOWN